Want to see XAIR full AI Analyst Report?
Beyond Air (XAIR) AI Stock Analysis
Beyond Air
(NASDAQ:XAIR)
The score is held down primarily by very weak financial performance (low gross margin, large losses, and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). Partially offsetting this are constructive earnings-call signals—reaffirmed guidance, improving gross margin, and commercial progress—plus recent preliminary revenue momentum, though regulatory timing and dilution/listing-risk considerations remain key constraints.
Beyond Air (XAIR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 222.97K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -0.16
- Revenue Growth
- 60.75%
- EPS Growth
- 71.34%
- Country
- US
- Employees
- 54
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Beyond Air Business Overview & Revenue Model
Company Description
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric...
How the Company Makes Money
Beyond Air’s business model is centered on commercializing its LungFit nitric oxide delivery platform and any related consumables or service components tied to clinical use. Revenue is expected to be generated primarily through sales (or potential le...
Beyond Air Earnings Call Summary
The call conveyed a constructive, growth-oriented outlook: management strengthened the balance sheet via a financing, secured important commercial partnerships (including a third national GPO), expanded international distribution, and showed improving unit economics (gross margin up to 13%) while reducing R&D spend. The company reaffirmed 2026 guidance and provided an ambitious multi‑year revenue target for 2027 tied to the potential Gen II LungFit PH launch. Key risks highlighted include flat current revenue, ongoing net losses and cash burn, increased other expense, and regulatory timing uncertainty for Gen II approval. On balance, the positives around financing, commercial traction, margin improvement, and a doubled pipeline outweigh the near-term operational and regulatory risks.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Beyond Air reaffirmed calendar 2026 revenue guidance of $8.0 million (about 15% growth over 2025) — expressly excluding any Gen II LungFit PH revenue — and reiterated 2027 guidance of $16–18 million (which includes potential Gen II revenue and implies >110% growth at the midpoint versus 2026); management said Gen II remains under FDA review with a potential H2 2026 approval (likely Q4, timing subject to the FDA) and that pilots and commercial preparations are underway. For context, Q2 revenue was $1.8M (H1 roughly $3.7M, implying about $4.3M in H2 to hit the $8M target), gross margin improved to 13% (vs. 9% year‑ago) marking a third consecutive quarter of positive gross profit, net loss was $7.9M (−$11.00 per share), cash and equivalents were $15.2M as of June 30 (pre‑financing), and the company has up to $30M of financing available ($10M upfront, $20M contingent via warrants) while expanding its commercial footprint (pipeline doubled in 5–6 months, distribution in >40 countries, and a third national GPO added alongside Premier and Vizient).
Beyond Air Financial Statement Overview
Summary
Early revenue traction is emerging (FY2026 revenue ~$7.7M; TTM up ~10% YoY), but fundamentals remain very weak: TTM gross margin is ~4% with extremely large losses versus revenue (TTM net margin around -436%) and continued heavy cash burn (TTM FCF about -$20.0M). Balance-sheet risk is elevated due to thin equity (~$2.0M TTM) and reliance on external funding despite improved leverage on the TTM snapshot.
Income Statement
18Very NegativeBalance Sheet
34NegativeCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.69M | 7.68M | 3.71M | 1.16M | 0 | 0 |
| Gross Profit | 321.00K | 252.00K | -1.66M | -1.31M | -555.00K | 0 |
| EBITDA | -29.62M | -30.68M | -41.89M | -59.03M | -58.20M | -42.70M |
| Net Income | -33.49M | -33.25M | -46.63M | -60.24M | -55.82M | -43.18M |
Balance Sheet | ||||||
| Total Assets | 32.89M | 35.38M | 30.06M | 56.96M | 68.75M | 99.20M |
| Cash, Cash Equivalents and Short-Term Investments | 15.22M | 11.64M | 6.92M | 34.47M | 45.88M | 80.24M |
| Total Debt | 23.60M | 23.38M | 11.69M | 17.84M | 3.59M | 3.49M |
| Total Liabilities | 30.05M | 29.18M | 15.72M | 29.77M | 26.72M | 20.99M |
| Stockholders Equity | 2.00M | 6.13M | 13.58M | 25.05M | 37.91M | 72.70M |
Cash Flow | ||||||
| Free Cash Flow | -19.60M | -19.17M | -44.10M | -61.76M | -36.89M | -24.51M |
| Operating Cash Flow | -18.56M | -18.14M | -38.22M | -56.02M | -33.01M | -23.13M |
| Investing Cash Flow | -3.79M | -3.67M | 14.90M | -12.23M | -20.59M | -1.45M |
| Financing Cash Flow | 28.08M | 29.09M | 16.65M | 43.17M | 2.70M | 79.45M |
Beyond Air Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XAIR, the sentiment is Negative. The current price of 2.24 is below the 20-day moving average (MA) of 2.29, below the 50-day MA of 3.04, and below the 200-day MA of 10.47, indicating a bearish trend. The MACD of -0.24 indicates Negative momentum. The RSI at 39.66 is Neutral, neither overbought nor oversold. The STOCH value of 72.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XAIR.
Beyond Air Risk Analysis
Beyond Air disclosed 74 risk factors in its most recent earnings report. Beyond Air reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskBeyond Air Peers Comparison
Overall Rating
HYPR55Neutral
LUNG53Neutral- XAIR45Neutral
COCH44Neutral
TLSI42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HYPR | 55Neutral | $76.10M | -1.87 | -100.30% | ― | 53.16% | 27.17% |
| LUNG | 53Neutral | $129.06M | -3.00 | -98.23% | ― | -3.15% | 28.45% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| XAIR | 45Neutral | $3.73M | -0.04 | -462.50% | ― | 60.75% | 71.34% |
| COCH | 44Neutral | $51.31M | -0.98 | 1719.71% | ― | -6.76% | 42.70% |
| TLSI | 42Neutral | $227.83M | -2.85 | 273.71% | ― | 25.25% | -9.85% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XAIR | Beyond Air | 2.24 | -36.76 | -94.26% | |
| LUNG | Pulmonx Corporation | 3.00 | 1.17 | 64.21% | |
| HYPR | Hyperfine Inc. | 0.72 | -0.41 | -36.55% | |
| TLSI | Trisalus Life Sciences, Inc. | 3.70 | -1.01 | -21.44% | |
| COCH | Envoy Medical, Inc. Class A | 6.63 | -1.01 | -13.19% |
Beyond Air Corporate Events
Beyond Air Reports Record Preliminary Quarterly Revenue Growth
PositiveBeyond Air reported preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, marking its highest quarterly revenue to date and representing 30% sequential growth and 27% year-on-year growth. The gains ref...
Beyond Air Formalizes CEO Agreement, Boosts CFO Compensation
PositiveOn September 23, 2026, Beyond Air, Inc. entered into an employment agreement with Chief Executive Officer Robert Goodman, formalizing his role after his appointment on March 27, 2026. The agreement, which has no fixed term, sets a minimum annual base...
Beyond Air secures financing and expands LungFit PH access
PositiveBeyond Air reported financial results for the quarter ended June 30, 2026, posting $1.8 million in revenue and a net loss of $7.9 million, while gross margin improved to 13% and research and development spending declined year on year. The company end...
Beyond Air Regains Nasdaq Compliance After Reverse Stock Split
PositiveOn April 7, 2026, Beyond Air, Inc. received notice from Nasdaq that it was not in compliance with the exchange’s minimum bid price rule, triggering a review of its listing status. On May 28, 2026, a Nasdaq Hearings Panel allowed the company to...
Beyond Air Announces At-the-Market Private Placement Financing
PositiveOn July 29, 2026, Beyond Air entered into a securities purchase agreement with institutional healthcare investors and certain directors and executives for a private placement of common stock, pre-funded warrants and Series A and Series B warrants, al...
Beyond Air Implements Reverse Stock Split to Maintain Listing
NegativeBeyond Air, Inc. held a special meeting of stockholders on June 18, 2026, where investors approved a 1-for-20 reverse stock split of the company’s outstanding common shares. The reverse split was implemented through a certificate of amendment f...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026